LAM-003 exhibits potent antileukemic activity in AML mouse models. (A) Kaplan-Meier survival analysis of a MOLM-13 systemic model in which mice were dosed orally with vehicle or with LAM-003 (75 or 150 mg/kg daily). Statistical significance was calculated by using the log-rank (Mantel-Cox) test. **P = .005 for LAM-003 75 mg/kg vs vehicle; **P = .008 for LAM-003 150 mg/kg vs vehicle. (B) Kaplan-Meier analysis of animal survival of mice inoculated with MOLM-13 cells systemically and treated with LAM-003 orally, venetoclax orally, or the combination as indicated once daily. Statistical significance was calculated by using the log-rank (Mantel-Cox) test. **P = .008 for LAM-003 vs vehicle; ***P = .0006 for the drug combination vs vehicle.